Efficacy of Intra-arterial Norcantharidin in Suppressing Tumour 14C-labelled Glucose Oxidative Metabolism in rat Morris Hepatoma

HPB Surgery

Volumn 10, Issue 2, 1996, Pages 65-72

  Mack, Peter ^a   Ha, Xiao Fang ^a   Cheng, Li Yao ^c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NONE

Author keywords

Adriamycin; glucose oxidation; hepatic artery ligation; liver cancer; Mylabris Cantharidin

Indexed keywords

ANTINEOPLASTIC AGENT; CANTHARIDIN; CARBON 14; CARBON DIOXIDE; DOXORUBICIN; NORCANTHARIDIN;

AEROBIC METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; CULTURE MEDIUM; DEMETHYLATION; DRUG EFFICACY; GLUCOSE METABOLISM; GLUCOSE OXIDATION; HEPATIC ARTERY LIGATION; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL CARCINOMA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE CULTURE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CARBON RADIOISOTOPES; CARCINOMA, HEPATOCELLULAR; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; GLUCOSE; HEPATIC ARTERY; INFUSIONS, INTRA-ARTERIAL; LIGATION; LIVER NEOPLASMS, EXPERIMENTAL; MALE; OXIDATION-REDUCTION; RATS; RATS, INBRED BUF;

EID: 0029850794     PISSN: 08948569     EISSN: 16078462     Source Type: Journal    
DOI: 10.1155/1996/63403     Document Type: Article

References (26)

1. Wang, G.S. (1980) Antitumor studies of mylabris and its development. (Chinese) Chinese Pharmaceutical Bulletin., 3, 23–26.
2. Wang, G.S. (1989) Medical uses of mylabris in ancient China and recent studies. J.Ethnopharmacol., 26, 147–162.
3. Wang, G.S. (1983) Hydrolysis and demethylation of cantharidin on the relief of its urinary irritation. (Chinese). Chinese Pharmaceutical Bulletin., 18(7), 18–19.
4. Wang, G.S. (1976) Pharmacology and clinical trials of mylabris and camptotheca acuminata. (Chinese). Beijing Research Information on Prevention and Treatment of Tumors., 1, 60–62.
5. Chen, R.T., Hua, Z., Yang, J.L. et.al. (1977) Studies on antitumor actions of cantharidin. (Chinese) National Medical Journal of China., 57(8), 475–48.
6. Dong, C., Cheng, F.H., Jin, T.Y., Li, B.M. (1982) Observations on the antitumor effect with norcantharidin in vitro. (Chinese) Yixue Ziliao (Health Bureau of Fuzhou Military Region)., 1, 52–53.
7. Wang, G.S., Huang, J.K., Lu, F.X., et al. (1986) Results of clinical trials in 244 cases of primary hepatoma with norcantharidin. (Chinese). Chinese Pharmaceutical Bulletin., 21(2), 90–93.
8. Yi, S.N., Wass, J., Vincent, P., Iland, H. (1991) Inhibitory effect of norcantharidin on K562 human myeloid leukaemia cells in vitro. Leuk.Res., 15, 883–886.
9. Shimi, I.R., Zaki, Z., Shoukry, S., Medhat, A.M. (1982) A new antitumor substance, 7-oxabicyclo(2.2.1)-5-heptene-2, 3-dicarboxylic anhydride. Eur. J. Cancer Clin. Oncol., 18, 785–793.
10. Warburg, O. (1930) The metabolism of tumours. London: Constable & Co.
11. Zamecnik, P.C., Loftfield, R.B., Stephenson, M.L., Steele, J.M. (1951) Studies on the carbohydrate and protein metabolism of the rat hepatoma. Cancer Res., 11, 592–602.
12. 14 -labelled carbohydrate intermediates in tumor and normal tissue. Cancer Res., 11, 571–584.
13. Mack, P., Ahren, B., Jeppsson, B., Zuxing, K., Bengmark, S. (1988) Influence of 2-Deoxy-D-glucose and arterial ischaemia on glucose oxidative metabolism and growth of liver cancer Eur. J. Cancer Clin. Oncol., 24, 1433–1437.
14. Morris, H.P., Dyer, H.M., Wager, B.P., Miyaji, H., Rechcigi, M.Jr. (1964) Some aspects of the development, biology and biochemistry of rat hepatomas of different growth rate. Adv. Enzyme Regul., 2, 321–333.
15. Yang, R., Rescorla, F.J., Reilly, C.R., Faught, P.R., Sanghvi, N.T., Lumeng, L., Franklin, T.D., and Grosfeld, J.L. (1992) A reproducible rat liver cancer model for experimental therapy: Introducing a technique of intrahepatic tumor transplantation. J.Surg. Res., 52, 193–198.
16. Liu, X.H., Blazsek, M.C., Legras, S., Marion, S., Quittet, P., Anjo, A., Wang, G.S., Misset, J.L. (1995) Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells. Eur. J. Cancer. (In press).
17. Shapot, V.S. (1972) Some biochemical aspects of the relationship between the tumor and the host. Adv. Cancer Res., 15, 253–286.
18. Erichsén, C., Christenson, P.I., Eriksson, G., Yngner, T., Jönsson, P.E., Stenram, U. (1986) Effects of administration routes on the uptake of uridine and 5-fluorouridine into an adenocarcinoma transplated to rat liver. J Surg Oncol., 33, 76–80.
19. Ensminger, W.D., Rosowsky, A., Raso, V. et al. (1987) A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2’-deoxyuridine and 5-fluorouracil. Cancer Res., 38, 3784–3792.
20. Fortner, J.G., Mulcare, R.J., Solis, A., Watson, R.C., Golbey, R.B. (1973) Treatment of primary and secondary liver cancer by hepatic artery ligation and infusion chemotherapy. Ann. Surg., 178, 162–172.
21. Breedis, C., Young G. (1954) The blood supply of neoplasms in liver. Am. J. Pathol., 30, 969–985.
22. Ackerman, N.B., Lien, W.M., Kondi, E.S., Silverman, N.A. (1969) The blood supply of experimental liver metastases. I. The distribution of hepatic artery and portal vein blood to “small” and “large” tumors. Surgery, 66, 1067–1072.
23. Nilsson, L.A.V., Zettergren, L. (1967) Effect of hepatic artery ligation on induced primary liver carcinoma in rats. Acta. Path. et Microbiol. Scandinav., 71, 187–193.
24. Nilsson, L.A.V. (1966) Therapeutic hepatic artery ligation in patients with secondary liver tumors. Rev. Surg., 23, 374–376.
25. Balasegaram, M. (1972) Complete hepatic dearterialization for primary carcinoma of the liver. Amer. J. Surg., 124, 340–345.
26. Koehler, R.E., Korobkin, M., Lewis. F. (1975) Arteriographic demonstration of collateral arterial supply to the liver after hepatic artery ligation. Radiology, 117, 49–54.